Clicky

Premier Biomedical(BIEI)

Description: Premier Biomedical, Inc. is a research-based company that intends to discover and develop medical treatments for humans, specifically focusing the treatment of Cancer, Multiple Sclerosis (MS), Neuropathic Pain, Amyotrophic Lateral Sclerosis (ALS/Lou Gehrig's Disease), Fibromyalgia, Traumatic Brain Injury (TBI), Alzheimer's disease (AD), and Blood Sepsis and Viremia. The Company intends to develop its Sequential-Dialysis Technique, to target Cancer, Alzheimer's disease, ALS, Blood Sepsis, Leukemia and other life-threatening cancers. The Sequential-Dialysis Technique is a methodology for the removal of those molecules, which are harmful and responsible for causing diseases. Its Sequential-Dialysis Technique method removes those excitatory neural transmitters that cause the death of those cells. It also intends to develop Feldetrex, a candidate drug, for the treatment of MS, Fibromyalgia and TBI. Feldetrex utilizes a low dosage of Naltrexone to increase endogenous enkephalins10.


Keywords: Medicine Cancer Pain Treatment Of Cancer Alzheimer's Disease Dialysis Leukemia Multiple Sclerosis Amyotrophic Lateral Sclerosis Neuropathic Pain Fibromyalgia Sepsis Molecules Traumatic Brain Injury Sclerosis Osage Brain Injury Enkephalin Naltrexone Treatment Of Ms

Home Page: www.premierbiomedical.com

PO Box 25
Jackson Center, PA 16133
United States
Phone: 724 633 7033


Officers

Name Title
Mr. David Caplan Pres, Chairman of Directors, Sec. & Treasurer
Mr. Carl Eller Marketing & Planning Vice-Pres

Exchange: PINK

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 0
Price-to-Sales TTM: 112.0348
IPO Date:
Fiscal Year End: December
Full Time Employees: 0
Back to stocks